If this message is not displayed correctly, click here.

No 121, January 2018

Image

200 News Communications Published on ENP

The ENP news, featured through European Nephrology Portal (an ERA-EDTA initiative), is an online open-access nephrology data provider, produced by the ENP medical writing team and medical news editors. ENP news covers the latest developments and researches in nephrology, dialysis and transplantation using data from relevant studies published in the most prestigious nephrology and health journals.

Shortly after ENP was launched, in May 2016, the portal started publishing news on a daily basis. Today, it is our honour to announce that the ENP has reached 200 published news!

Read here the full article about ENP news.

Image

Young Nephrologists’ Platform - call for candidatures

The Young Nephrologists’ Platform (YNP) is pleased to announce that there is an open call for a position within its Board. For more information on the eligibility criteria and on how to apply, we kindly refer you to the YNP webpage. The deadline for applications is February 28, 2018 at 16:00 CET. For any additional information, please contact YNP at ynp@era-edta.org.

The YNP looks forward to receiving all eligible candidates!

EURODOPPS – call for proposals

EURODOPPS is looking for external investigators. Visit the ERA-EDTA Registry website for more information and download the Research Proposal Form that must be submitted, together with a brief letter of intent, by February 5, 2018.

In order to be eligible, all applicants must have proven extensive experience in data analysis (assistance from the ERA-EDTA Registry office with the statistics and interpretation of the results will not be available).

NDT and CKJ articles

Just published online: read the latest NDT and CKJ articles

Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation

In most patients with chronic kidney disease (CKD) and atrial fibrillation, oral anticoagulation is indicated to lower their thromboembolic risk. There is evidence suggesting that patients in CKD stage 3 benefit even more from this therapy than patients with normal kidney function. Therefore, the use of new anticoagulants (NOACs) is increasing, especially because they seem to have a better benefit–risk profile than classical agents. But the optimal use of these new agents in patients with CKD has still to be discovered, because this patients’ group has so far been excluded from all phase 3 studies with NOACs. It is known that NOACs have a variable degree of renal elimination – so what is the best choice of anticoagulation in patients with advanced and, in particular, end-stage renal disease? This review paper published in NDT summarizes the state-of-the-art knowledge about the use of NOACs in CKD patients and provides CKD stage-specific recommendations.

Nephrologists should be more aware of the concept of frailty!

Frailty is common in patients with chronic kidney disease (CKD). The prevalence of frailty in the community-dwelling older adult population is reported to be 11%, whereas studies have reported a frailty prevalence of > 60% in dialysis-dependent CKD patients. The authors of this paper published in CKJ expressed the view that nephrologists should be more aware of the concept of frailty. Although they did not recommend one specific frailty assessment approach, they emphasized the necessity of identifying frail people among kidney patients. This would be important because frailty is independently linked with adverse clinical outcomes in all stages of CKD and has been repeatedly shown to be associated with an increased risk of mortality and hospitalization. Recognizing frailty would prompt a holistic assessment of the patient to address risk factors.

Do not miss the “Kidney Meets Liver” meeting on March 16, 2018 in Amsterdam (The Netherlands)

The kidney and the liver are linked through many intrinsic pathways. As such, the ERA-EDTA and EASL International Liver Foundation are linking together to jointly tackle key issues. This first meeting will provide an innovative and interactive program addressing two emerging epidemics that have a great impact on both the kidney and the liver: viral hepatitis and non-alcoholic fatty liver disease (NAFLD).

ERA-EDTA Mission
Web Site
 
secretariat@era-edta.org
 
 
Facebook
 
Twitter
 
Google+
 
LinkedIn
 
Instagram
 
YouTube
 
Vimeo
 

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.